Streetbeat News

Analyst Ratings

BKNG

A significant bearish stance has been taken on Booking Holdings (NASDAQ:BKNG) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is 80% bearish and 20% bullish. The whales have been targeting a price range from $1540.0 to $3800.0 for Booking Holdings over the last 3 months. Argus Research has downgraded its action to Buy with a price target of $3677.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:15 pm

IONS

RHHBY

Ionis Pharmaceuticals Inc has entered an agreement with Roche Holdings AG for two early-stage programs for RNA-targeting investigational medicines for Alzheimer's and Huntington's diseases. Roche gains exclusive worldwide rights and will be responsible for clinical development, manufacturing, and commercialization. Ionis will receive a $60 million upfront payment from Roche and is eligible to receive development, regulatory, and commercial milestone payments and tiered royalties. Analysts see Ionis as the premier enterprise developing Antisense Oligonucleotides therapies but foresee near-term commercial headwinds.

Portfolio Pulse from Vandana Singh

September 27, 2023 | 5:13 pm

RKLB

TD Cowen analyst Cai von Rumohr maintains an Outperform rating on Rocket Lab USA (NASDAQ:RKLB) but lowers the price target from $9.5 to $8.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 5:12 pm

COST

B of A Securities analyst Robert Ohmes maintains a Buy rating on Costco Wholesale (NASDAQ:COST) and raises the price target from $575 to $610.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 5:10 pm

SEEL

Seelos Therapeutics Inc (NASDAQ:SEEL) announced encouraging preclinical data from an in vivo study of SLS-005 in an aggressive Alzheimer's disease non-human primate model. The study showed a 46% reduction in tau protein and an 18% reduction in NfL, a protein biomarker. Top-line data from the SLS-005 registrational Phase 2/3 trial in ALS is expected to be released in Q4 of 2023. However, Seelos' Phase 2 study of SLS-002 for Acute Suicidal Ideation and Behavior failed to meet the pre-defined primary endpoint. SEEL shares are up 13.50% at $0.20.

Portfolio Pulse from Vandana Singh

September 27, 2023 | 5:07 pm

MRMD

MSOS

MariMed CEO Jon Levine, speaking at the Benzinga Cannabis Capital Conference, urged investors to compare the company's balance and income statements to its competitors, claiming that MariMed has one of the strongest balance sheets in the industry.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 5:07 pm

ARGX

BHVN

IMVT

JNJ

PFE

Pfizer's subsidiary Biohaven released an updated investor presentation with additional data on its BHV-1300 program, a potential competitor to FcRn-targeting therapeutics. The data shows that BHV-1300 takes a direct approach by targeting IgG itself for degradation, which sets it apart from competitors. Biohaven's data shows a substantial reduction in IgG levels of over 90% based on experiments conducted on nonhuman primates. Biohaven's shares are up 27% at $22.42.

Portfolio Pulse from Vandana Singh

September 27, 2023 | 5:05 pm

AMZN

META

MSFT

Amazon.com, Inc. (NASDAQ:AMZN) is facing an antitrust lawsuit filed by the FTC and 17 state governments, alleging the company is using anti-competitive tactics to maintain its market dominance. The lawsuit has led to a 1.4% drop in Amazon's shares, hitting a 3-month low. Despite this, several analysts maintain positive outlooks for the company, with average one-year price target at $172, a 39% increase from the current valuation.

Portfolio Pulse from Piero Cingari

September 27, 2023 | 5:05 pm

LTH

In the last quarter, Life Time Group Hldgs (NYSE:LTH) received various analyst ratings, with 1 bullish, 2 somewhat bullish, 2 indifferent, and 1 somewhat bearish. The company's average 12-month price target is $21.67, up 3.19% from the previous average of $21.00. Analysts' ratings are based on company financial statements, insider communications, and sector trends.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:01 pm

HSY

Hershey's (NYSE:HSY) short percent of float has risen 4.49% since its last report, with 3.44 million shares sold short, which is 2.56% of all regular shares available for trading. It would take traders 2.72 days to cover their short positions on average. An increase in short interest can signal that investors have become more bearish. Hershey's peer group average for short interest as a percentage of float is 4.53%, which means the company has less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:01 pm